Document is current

Article History

Received: 18 October 2024

Accepted: 14 December 2024

First Online: 18 January 2025

Disclosures

: James J. Harding has received research support from NCI P30-CA008748, NCI U01 CA238444 04, the Society of Memorial Sloan Kettering Cancer Center, Experimental Therapeutics Center, and Cycle for Survival; received additional research support from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate Biopharma, Loxo @ Lilly, Novartis, Polaris, Pfizer, Tvardi, Zymeworks, and Yiviva; and received consulting fees from Adaptimmune, AstraZeneca, Bristol Myers Squibb, Exelexis, Elevar, Eisai, Genoscience (uncompensated), Hepion, Imvax, Merck (DSMB) Medivir, QED, RayzeBio, Servier, Tempus, Tyra, and Zymeworks (uncompensated). Jeffrey Drebin declares equity shares of ALNY and IONS purchased via a brokerage account. Andrea Cercek has participated in Advisory Boards for Abbvie, Amgen, Agents, Daiichi Snayko, GSK, Merck, Janssen, Pfizer/Seagen, Regeneron, and Roche, and has received research funding from GSK and Pfizer/Seagen. Eileen O'Reilly has received research funding (paid to her institution) from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, and Agenus; undertaken consulting work and is a member of the Data Safety Monitoring Board for Arcus, AstraZeneca, Ability Pharma, Alligator BioSciences, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicines, Regeneron, Merus, and Tango; Abbvie (spouse); and ‘other’ disclosures pertaining to the American Association of Cancer Research, American Society of Clinical Oncology, Imedex, Research To Practice, and SU2C. Alice Wei has undertaken consulting work and is a member of the Data Safety Monitoring Board for Histosonics, and has received clinical trial funding from Ipsen. John Strickler has participated in consultancy or advisory roles for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Beigene, BMS, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Ipsen, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, and Xilio Therapeutics; has stock options in Triumvira Immunologics; and has received research funding from or undertaken contracted research for Abbvie, Amgen, Apollo Therapeutics, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche/Genentech. Jeremy Sharib, Kristen E. Rhodin, Annie Liu, Sarah McIntyre, Alex Bartholomew, Sabran Masoud, Isabel DeLaura, Nancy E. Kemeny, Ghassan K. Abou-Alfa, Diane Reidy-Lagunes, Louise Catherine Connell, Imane El Dika, Vinod P. Balachandran, Kevin C. Soares, T. Peter Kingham, Michael I. D’Angelica, Hope Uronis, S. David Hsu, Michael Morse, Sabino Zani, Peter J. Allen, William R. Jarnagin, and Michael E. Lidsky have no conflicts of interest to declare that may be relevant to the contents of this study.